The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
Abstract
Objective: A previous phase 3 study showed significant improvement in walking ability in multiple sclerosis (MS) patients treated with oral, extended‐release dalfampridine (4‐aminopyridine) 10mg twice daily. The current study was designed to confirm efficacy and further define safety and pharmacodynamics. Methods: This was a 39‐center, double‐blind trial in patients with definite MS of any course type. Participants were randomized to 9 weeks of treatment with dalfampridine (10mg twice daily; n = 120) or placebo (n = 119). Response was defined as consistent improvement on the Timed 25‐Foot Walk, with percentage of timed walk responders (TWRs) in each treatment group as the primary outcome. The last on‐treatment visit provided data from 8 to 12 hours postdose, to examine maintenance of effect. Results: One patient from each group was excluded from the modified Intention to Treat population. The proportion of TWRs was higher in the dalfampridine group (51/119 or 42.9%) compared to the placebo group (11/118 or 9.3%, p < 0.0001). The average improvement in walking speed among dalfampridine‐treated TWRs during the 8‐week efficacy evaluation period was 24.7% from baseline (95% confidence interval, 21.0–28.4%); the mean improvement at the last on‐treatment visit was 25.7%, showing maintenance of effect over the interdosing period. There were no new safety findings. Interpretation: This interventional study provides class 1 evidence that dalfampridine extended‐release tablets produce clinically meaningful improvement in walking ability in a subset of people with MS, with the effect maintained between doses. Ann Neurol 2010;68:494–502
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS.
Ashworth, B. (1964) · PubMed · Cited by 1,475
Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12)
Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R., & Thompson, A. J. (2003) · Neurology · doi:10.1212/wnl.60.1.31 · Cited by 821
Goodman, A. D., Brown, T. R., Krupp, L. B., Schapiro, R. T., Schwid, S. R., Cohen, R., Marinucci, L. N., & Blight, A. R. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60442-6 · Cited by 549
Self-citationJudge, S. I. V., & Bever, C. T. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.10.006 · Cited by 268
Dose comparison trial of sustained-release fampridine in multiple sclerosis
Goodman, A. D., Brown, T. R., Cohen, J. A., Krupp, L. B., Schapiro, R., Schwid, S. R., Cohen, R., Marinucci, L. N., & Blight, A. R. (2008) · Neurology · doi:10.1212/01.wnl.0000326213.89576.0e · Cited by 179
Self-citationThe effects of 4‐aminopyridine in multiple sclerosis patients
Bever, C. T., Young, D., Anderson, P. A., Krumholz, A., Conway, K. L., Leslie, J. L., Eddington, N. D., Plaisance, K. I., PANITCH, H. S., Dhib-Jalbut, S. S., et al. (1994) · Neurology · doi:10.1212/wnl.44.6.1054 · Cited by 156
Goodman, A. D., Cohen, J. A., Cross, A. H., Vollmer, T. L., Rizzo, M., Cohen, R., Marinucci, L. N., & Blight, A. R. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458506069538 · Cited by 156
Self-citationvan Diemen, H. A. M., Polman, C. H., van Dongen, T. M. M. M., Loenen, A. C. V., Nauta, J. J. P., Taphoorn, M. J. B., van Walbeek, H. K., & Koetsier, J. C. (1992) · Annals of Neurology · doi:10.1002/ana.410320203 · Cited by 137
Cited by
Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30481-1 · Cited by 1,797
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Motl, R. W., Cohen, J. A., Benedict, R., Phillips, G., LaRocca, N., Hudson, L. D., Rudick, R., & Multiple Sclerosis Outcome Assessments Consortium (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517690823 · Cited by 407
Cohen, J. A., Reingold, S. C., Polman, C. H., & Wolinsky, J. S. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70059-5 · Cited by 233
Potassium Channel Kv1.3 Is Highly Expressed by Microglia in Human Alzheimer's Disease
Rangaraju, S., Gearing, M., Jin, L.-W., & Levey, A. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141704 · Cited by 137
Metadata
- Authors
- Goodman, A. D., Brown, T. R., Edwards, K. R., Krupp, L. B., Schapiro, R. T., Cohen, R., Marinucci, L. N., Blight, A. R., & on behalf of the MSF204 Investigators
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-10
- Volume
- 68
- Issue
- 4
- Pages
- 494-502
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2145583517
- Cited by
- 374
- References
- 13
- FWCI
- 24.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. https://app.cochat.ai/papers/10.1002/ana.22240
- The paper
- Goodman, A. D., Brown, T. R., Edwards, K. R., Krupp, L. B., Schapiro, R. T., Cohen, R., Marinucci, L. N., Blight, A. R., & on behalf of the MSF204 Investigators. (2010). A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of Neurology. https://doi.org/10.1002/ana.22240
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.